[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346611-105":59,"doc-detail-346611-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-urological-cancers-with-car-t-cell-therapy-current-landscape-and-future-directions","Targeting urological cancers with CAR-T cell therapy - current landscape and future directions","","Urological cancers, including renal, bladder, and prostate cancers, represent highly prevalent solid tumors with substantial morbidity and mortality. Building on the success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies, research has advanced toward adapting this approach for urological disease. Preclinical work shows promising antitumor activity and multiple clinical trials are underway to assess safety and efficacy. Key barriers include tumor heterogeneity, antigen escape, an immunosuppressive tumor microenvironment, and treatment-related toxicities. Future progress requires combinatorial design, improved efficacy-to-toxicity balance, broader patient validation, and more individualized regimens.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-urological-cancers-with-car-t-cell-therapy-current-landscape-and-future-directions/346611/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-urological-cancers-with-car-t-cell-therapy-current-landscape-and-future-directions/346611.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which urological cancers are covered in the review?","Question",{"text":113,"@type":114},"The review focuses on renal, bladder, and prostate cancers, outlining their burden and the rationale for applying CAR-T cell therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the main challenges limiting CAR-T therapy in urological cancers?",{"text":118,"@type":114},"Challenges include tumor heterogeneity, antigen escape, an immunosuppressive tumor microenvironment (TME), and treatment-related toxicities.",{"name":120,"@type":111,"acceptedAnswer":121},"What future research directions does the review emphasize?",{"text":122,"@type":114},"Future work should prioritize combinatorial strategies, optimizing efficacy versus toxicity, validating results in larger and more diverse cohorts, and developing more precise individualized treatment plans.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346611,1790334000,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Chen et al. Journal of Translational Medicine (2026) 24:333  \n[https://doi.org/10.1186/s12967-026-07737-7](https://doi.org/10.1186/s12967-026-07737-7)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nTargeting urological cancers with CAR-T cell therapy: current landscape and future directions  \nKai Chen1†, Yifan Wang2†, Pu Zhang2†, Yi He1, Dilinaer Wusiman3, Koo Han Yoo4, Lede Lin5, Qibo Hu6, Wangjian Wu1, Lingfeng Wu1*, Qi Zhang2* and Dechao Feng2,7*  \nAbstract  \nBackground Urological cancers, including renal, bladder, and prostate cancers, are among the most prevalent solid tumors. The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has spurred its exploration for treating urological cancers.  \nMain body In the past decade, preclinical studies have demonstrated promising antitumor activity of CAR-T cells against urological cancers. Meanwhile, multiple clinical trials are currently underway to evaluate their safety and efficacy. However, significant challenges impede the efficacy of CAR-T cell therapy in urological cancers, including tumor heterogeneity and antigen escape, the immunosuppressive tumor microenvironment (TME), and treatmentrelated toxicities. To address these limitations, current research efforts are actively explored on several strategies, such as identifying novel target antigens, engineering CAR structurally optimized, and reversing the immunosuppressive TME. This review systematically summarizes these recent research advances for renal, bladder, and prostate cancers. Conclusions Accumulating evidence supports the therapeutic potential of CAR-T cell therapy for urological cancers. To realize its clinical promise, future research needs focus on design of combinatorial strategies, optimizing the balance between efficacy and toxicity, validating findings in larger and more diverse patient cohorts, and developing more precise, individualized treatment regimens.  \nKeywords CAR-T cell therapy, Urological cancers, Immunotherapy, Tumor microenvironment, Clinical trials  \n†Kai Chen, Yifan Wang and Pu Zhang contributed equally to this work.  \n*Correspondence: Lingfeng Wu [sandy4813@163.com](sandy4813@163.com)[ ](sandy4813@163.com)Qi Zhang  \n[clinic@zju.edu.cn](clinic@zju.edu.cn); [zhangqi1@hmc.edu.cn](zhangqi1@hmc.edu.cn)  \nDechao Feng  \n[dechao.feng@ucl.ac.uk](dechao.feng@ucl.ac.uk)  \n1Department of Urology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jia Xing, Zhejiang, China  \n2Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, China  \n3Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA  \n4Department of Urology, Kyung Hee University, Seoul, South Korea 5Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China  \n6Department of Urology, Pediatric Urolith Centre, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Centre for Child Health, Hangzhou, Zhejiang, China  \n7Division of Surgery & Interventional Science, University College London, London W1W 7TS, UK  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not inclu","cbCaivoypr3ibGOa","https://ap.wps.com/l/cbCaivoypr3ibGOa","pdf",3100585,26,"English","# Abstract\n# Introduction\n# Main body\n## Preclinical and clinical progress\n## Major challenges in urological cancers\n## Strategies to overcome limitations\n# Conclusions","[{\"question\":\"Which urological cancers are covered in the review?\",\"answer\":\"The review focuses on renal, bladder, and prostate cancers, outlining their burden and the rationale for applying CAR-T cell therapy.\"},{\"question\":\"What are the main challenges limiting CAR-T therapy in urological cancers?\",\"answer\":\"Challenges include tumor heterogeneity, antigen escape, an immunosuppressive tumor microenvironment (TME), and treatment-related toxicities.\"},{\"question\":\"What future research directions does the review emphasize?\",\"answer\":\"Future work should prioritize combinatorial strategies, optimizing efficacy versus toxicity, validating results in larger and more diverse cohorts, and developing more precise individualized treatment plans.\"}]","Targeting urological cancers with CAR-T cell therapy - current landscape and future directions | PDF",1790062118,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/039aad26f1f752ca186e66d01024a600.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43dc2e5428617e9fed032a9751e10471.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a74d6241d3903cc70b58e3c650061a7.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52c095cd6ea9442d705cd0741ce1e222.webp",980,1306]